Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

This study is for adults with meningioma, a type of tumor that grows in the membranes covering the brain. Specifically, it focuses on patients whose tumors are showing signs of growth or progression despite previous treatments. The trial is comparing a targeted radioactive drug called 177Lu-DOTATATE against standard treatments such as bevacizumab or hydroxyurea. 177Lu-DOTATATE works by attaching to a specific protein on the surface of some tumor cells and delivering a dose of radiation directly to them.

To be eligible, you must have a confirmed diagnosis of grade 1, 2, or 3 meningioma that has grown recently according to your MRI scans. Because the study drug targets a specific protein, you will need to undergo a special PET scan to ensure your tumor has enough of that protein to be treated. You should not have a diagnosis of NF2-related schwannomatosis or a history of previous somatostatin-targeted therapies. You will also need to meet certain health requirements regarding your kidney function and blood cell counts.

If you participate, you will be randomly assigned to receive either the study drug or a standard treatment. Those receiving the study drug typically get four to six infusions spaced about four weeks apart. Throughout the study, you will have regular brain MRIs and PET scans to monitor the treatment. Before joining, you should talk with your doctor about your previous radiation doses and any other medications you are taking for tumor-related symptoms like swelling.